Bio-Pharm Archives - 17 중 16 번째 페이지

GC WellBeing Anticipates Strong Market Penetration in China with Placental Injections and Fillers

GC WellBeing Corporation Expected to See Stock Price Rise in H2 with Stable Sales Growth in Chinese Market Analysts predict that GC WellBeing Corporation will see a stable increase in…

Jang Jawon

2024-07-19

"Global Clinical Trials Shift from Europe to US and China"

The focus of global clinical trials is shifting from Europe to the United States and China, according to a recent market analysis. IQVIA, a global healthcare consulting firm, released…

Jang Jawon

2024-07-18

"SK Biopharm's Epilepsy Drug Excels in the U.S."... Growth Expected in the Second Half

SK Biopharm is expected to continue its performance growth in the second half of the year, driven by the stable sales growth of its epilepsy treatment, Cenobamate (marketed in the…

Jang Jawon

2024-07-17

DongA ST, Subsidiary MASH and Obesity Drug Clinical Results Expected This Year

Analysts in the securities industry suggest paying attention to the clinical results to be released later this year by DongA ST's subsidiary, NeuroBo Pharmaceuticals (NeuroBo). On the 12th, Seo Geunhee,…

Cheon Okhyeon

2024-07-16

Biosimilar Onslaught Dents Global Blockbuster Humira

The dominance of the autoimmune disease treatment Humira (active ingredient: adalimumab), once the world's best-selling drug, is waning. Sandoz's biosimilar Hyrimoz has rapidly gained market share, pulling down Humira's share,…

Cheon Okhyeon

2024-07-16

D&D Pharmatech "Confident in MASH and Obesity Drug Efficacy…Targeting 100 Trillion Won Market"

“The GLP-1 obesity treatment market is expected to grow to 100 trillion won( approximately 77 billion dollars) by 2030. Including metabolic-associated steatohepatitis (MASH), the market potential is even larger. D&D…

Jang Jawon

2024-07-11

A New Treatment Option Emerges for Non-Hodgkin's Lymphoma

A new treatment option for managing refractory blood cancer, specifically Diffuse Large B-Cell Lymphoma (DLBCL), has completed its approval process in Korea. This approval primarily targets high-risk patients who frequently…

Won Jonghyuck

2024-07-10

Hanmi Pharmaceutical Group Declares End to Management Dispute

The management dispute within Hanmi Pharmaceutical Group that has heated up the pharmaceutical and biotech industry for over 6months this year has come to an end. On the 10th, Lim…

Cheon Okhyeon

2024-07-10

Reasons to Watch HK Inno.N in the Second Half of the Year

HK Inno.N Corporation is emerging as a company to watch in the second half of the year, following strong performance and promising U.S. clinical trial results. On the 9th, the…

Cheon Okhyeon

2024-07-09

Celltrion Receives UK Approval for Asthma Drug Biosimilar 'Xolair'

Celltrion has announced that their biosimilar Omvoh (CT-P39), a treatment for allergic asthma and chronic idiopathic urticaria, has been approved by the UK's Medicines and Healthcare products Regulatory Agency (MHRA).…

Cheon Okhyeon

2024-07-09